tetano
Editor, Senior Moderator
J Infect Dev Ctries
. 2023 Mar 31;17(3):311-318.
doi: 10.3855/jidc.16982.
Outpatient treatment of COVID-19: an experience with 552 cases in Mexico
Raúl Romero-Cabello[SUP] 1 [/SUP], Raúl Romero-Feregrino[SUP] 2 [/SUP], Rodrigo Romero-Feregrino[SUP] 2 [/SUP], Berenice Muñoz-Cordero[SUP] 2 [/SUP], Samuel Sevilla-Fuentes[SUP] 3 [/SUP]
Affiliations
Abstract
Introduction: The impact of the coronavirus disease 2019 (COVID-19) pandemic has globally challenged health services, especially because when the pandemic first reached Mexico, in February 2020, there was no known effective and safe treatment. A treatment scheme was offered by the Institute for the Integral Development of Health (IDISA) in Mexico City from March 2020 to August 2021 when there were many patients with COVID-19. This report summarizes the experience managing COVID-19 with this scheme.
Materials and methods: This is a descriptive, retrolective study. The data was obtained from the case files of the patients who attended the IDISA from March 2020 to August 2021 with COVID-19. All the cases were treated with the scheme consisting of nitazoxanide, azithromycin, and prednisone. Various laboratory blood tests and chest computerized tomography scan were done. When indicated, supplementary oxygen, and another specific treatment were used. A standardized clinical recording was conducted for 20 days based on symptoms and systemic symptoms.
Results: Based on the World Health Organization criteria, the patients were classified according to the disease severity: 170 mild, 70 moderate, and 312 severe cases. The outcome was the discharge of 533 patients after their recovery, 16 were excluded from the study, and 6 died.
Conclusions: The use of nitazoxanide, azithromycin, and prednisone proved to be effective as it resulted in improvement of symptoms and in successful outcomes for the management of COVID-19 outpatients.
Keywords: Azithromycin; COVID-19; Nitazoxanide; Prednisone; treatment.
. 2023 Mar 31;17(3):311-318.
doi: 10.3855/jidc.16982.
Outpatient treatment of COVID-19: an experience with 552 cases in Mexico
Raúl Romero-Cabello[SUP] 1 [/SUP], Raúl Romero-Feregrino[SUP] 2 [/SUP], Rodrigo Romero-Feregrino[SUP] 2 [/SUP], Berenice Muñoz-Cordero[SUP] 2 [/SUP], Samuel Sevilla-Fuentes[SUP] 3 [/SUP]
Affiliations
- PMID: 37023433
- DOI: 10.3855/jidc.16982
Abstract
Introduction: The impact of the coronavirus disease 2019 (COVID-19) pandemic has globally challenged health services, especially because when the pandemic first reached Mexico, in February 2020, there was no known effective and safe treatment. A treatment scheme was offered by the Institute for the Integral Development of Health (IDISA) in Mexico City from March 2020 to August 2021 when there were many patients with COVID-19. This report summarizes the experience managing COVID-19 with this scheme.
Materials and methods: This is a descriptive, retrolective study. The data was obtained from the case files of the patients who attended the IDISA from March 2020 to August 2021 with COVID-19. All the cases were treated with the scheme consisting of nitazoxanide, azithromycin, and prednisone. Various laboratory blood tests and chest computerized tomography scan were done. When indicated, supplementary oxygen, and another specific treatment were used. A standardized clinical recording was conducted for 20 days based on symptoms and systemic symptoms.
Results: Based on the World Health Organization criteria, the patients were classified according to the disease severity: 170 mild, 70 moderate, and 312 severe cases. The outcome was the discharge of 533 patients after their recovery, 16 were excluded from the study, and 6 died.
Conclusions: The use of nitazoxanide, azithromycin, and prednisone proved to be effective as it resulted in improvement of symptoms and in successful outcomes for the management of COVID-19 outpatients.
Keywords: Azithromycin; COVID-19; Nitazoxanide; Prednisone; treatment.